Oncolytics Biotech Inc.
ONCY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7,515 | $2,809 | $4,083 | $4,552 |
| G&A Expenses | $6,232 | $2,803 | $2,819 | $3,461 |
| SG&A Expenses | $6,232 | $2,803 | $2,819 | $3,461 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $93 | $94 | $97 | $424 |
| Operating Expenses | $13,840 | $5,706 | $6,999 | $8,437 |
| Operating Income | -$13,840 | -$5,706 | -$6,999 | -$8,437 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$812 | -$374 | $312 | $443 |
| Pre-Tax Income | -$14,652 | -$6,080 | -$6,687 | -$7,994 |
| Tax Expense | -$252 | $85 | $0 | $23 |
| Net Income | -$14,400 | -$6,165 | -$6,687 | -$8,017 |
| % Margin | – | – | – | – |
| EPS | -0.14 | -0.068 | -0.079 | -0.1 |
| % Growth | -106.8% | 14.3% | 21% | – |
| EPS Diluted | -0.14 | -0.068 | -0.079 | -0.1 |
| Weighted Avg Shares Out | 101,315 | 91,000 | 84,631 | 76,090 |
| Weighted Avg Shares Out Dil | 101,315 | 91,000 | 84,631 | 76,090 |
| Supplemental Information | – | – | – | – |
| Interest Income | $100 | $104 | $123 | $152 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $93 | $94 | $97 | $98 |
| EBITDA | -$14,559 | -$5,612 | -$6,902 | -$8,339 |
| % Margin | – | – | – | – |